SYR 619
Alternative Names: SYR-619Latest Information Update: 02 Oct 2021
At a glance
- Originator Takeda San Diego
- Class Antihyperglycaemics; Small molecules
- Mechanism of Action Dipeptidyl peptidase 4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 11 May 2007 Discontinued - Preclinical for Type-2 diabetes mellitus in USA (unspecified route)
- 25 Jul 2005 Takeda and PPD have entered into an agreement providing Takeda with the development and marketing rigths to all DPP IV inhibitors that were previouslly granted to PPD by Syrrx (now Takeda San Diego)
- 01 Mar 2005 Syrrx has been acquired by Takeda and renamed Takeda San Diego